# Abbott Laboratories (ABT) FY2024 Annual Balance Sheet

- Company: Abbott Laboratories (ABT)
- Period: As of 2024-12-31
- Filing: FY2024 10-K, filed 2025-02-21, accession number 0001628280-25-007110
- Page: https://plicit.ai/financials/abt/fy2024-annual-balance-sheet
- Chart image: https://plicit.ai/charts/abt-fy2024-annual-balance-sheet-sankey.png

## Chart details

Balance sheet as of 2024-12-31. The chart shows assets, liabilities and equity at that date.

- **Assets**: 81,414,000,000 US dollars
- **Current assets**: 23,656,000,000 US dollars
- **Non-current assets**: 57,758,000,000 US dollars
- **Liabilities (calculated)**: 33,513,000,000 US dollars
- **Current liabilities**: 14,157,000,000 US dollars
- **Non-current liabilities**: 19,356,000,000 US dollars
- **Equity**: 47,901,000,000 US dollars
- **Noncontrolling interest**: 237,000,000 US dollars. Included in consolidated equity; this amount is not added again.
- **Land**: 528,000,000 US dollars. Part of Net property and equipment, drawn as one net amount.
- **Buildings**: 4,207,000,000 US dollars. Part of Net property and equipment, drawn as one net amount.
- **Equipment**: 15,517,000,000 US dollars. Part of Net property and equipment, drawn as one net amount.
- **Construction in progress**: 2,488,000,000 US dollars. Part of Net property and equipment, drawn as one net amount.
- **Less: accumulated depreciation and amortization**: negative 12,082,000,000 US dollars. Part of Net property and equipment, drawn as one net amount.
- **Cash and cash equivalents**: 7,616,000,000 US dollars
- **Trade receivables, less allowances of — 2024: $439; 2023: $444**: 6,925,000,000 US dollars
- **Finished products**: 3,700,000,000 US dollars
- **Other prepaid expenses and receivables**: 2,570,000,000 US dollars
- **Materials**: 1,654,000,000 US dollars
- **Work in process**: 840,000,000 US dollars
- **Investments, primarily bank time deposits and U.S. treasury bills**: 351,000,000 US dollars
- **Goodwill**: 23,108,000,000 US dollars
- **Deferred income taxes and other assets**: 16,459,000,000 US dollars
- **Net property and equipment**: 10,658,000,000 US dollars
- **Intangible assets, net of amortization**: 6,647,000,000 US dollars
- **Investments**: 886,000,000 US dollars
- **Other accrued liabilities**: 5,143,000,000 US dollars
- **Trade accounts payable**: 4,195,000,000 US dollars
- **Salaries, wages and commissions**: 1,701,000,000 US dollars
- **Current portion of long-term debt**: 1,500,000,000 US dollars
- **Dividends payable**: 1,024,000,000 US dollars
- **Income taxes payable**: 594,000,000 US dollars
- **Long-term debt**: 12,625,000,000 US dollars
- **Post-employment obligations and other long-term liabilities**: 6,731,000,000 US dollars
- **Earnings employed in the business**: 47,261,000,000 US dollars
- **Common shares, without par value Authorized — 2,400,000,000 shares Issued at stated capital amount — Shares: 2024: 1,991,472,630; 2023: 1,987,883,852**: 25,153,000,000 US dollars
- **Preferred shares, one dollar par value Authorized — 1,000,000 shares, none issued**: 0 US dollars
- **Noncontrolling interests in subsidiaries**: 237,000,000 US dollars
- **Common shares held in treasury, at cost — Shares: 2024: 259,774,639; 2023: 253,807,494**: negative 16,844,000,000 US dollars
- **Accumulated other comprehensive income (loss)**: negative 7,906,000,000 US dollars
- **Gross equity (calculated)**: 72,651,000,000 US dollars. Net equity plus the magnitudes of its negative contributions equals gross positive equity. The negative contributions enter this reconciliation as add-backs; their filed signs stay negative.

### Chart connections

- Assets equal liabilities plus consolidated equity. Consolidated equity includes noncontrolling interests when reported.
- Treasury shares and other negative equity contributions reduce equity.